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Abstract  
Rationale: Experimental evidence indicates that endothelin-1 stimulates sympathetic 
nervous system by activation of the subtype-A receptor. Aim of the present study was 
to assess the role of endogenous endothelin-1 in modulating sympathetic activity in 
essential hypertensive patients and in normotensive subjects. 
Methods and Results: In 15 hypertensive and 12 normotensive subjects blood 
pressure, heart rate and muscle sympathetic nervous activity were evaluated during 
intravenous 20’ infusion of BQ123 (0.1 mg/Kg/h), an ETA-receptor antagonist, and 
sodium-nitroprusside (0.4 µg/Kg/min). In hypertensive patients, blood pressure was 
similarly reduced by BQ123 and sodium-nitroprusside. In contrast, the increase in 
muscle sympathetic nervous system activity induced by BQ123 (from 52.0±4.9 to 
56.8±5.5 bursts/100hb, p<0.05 vs baseline) was significantly lower (p<0.05) than 
sodium nitroprusside (from 50.6±4.9 to 61.1±5.1 bursts/100hb, p<0.05 vs baseline). 
In normotensive subjects, BQ123 did not modify blood pressure or sympathetic 
activity, but caused a significant increase in heart rate. In a subgroup (n=9) of 
normotensive subjects we administered BQ123 at a dose (0.2 mg/Kg/h) 
equidepressor to sodium nitroprusside, inducing a blunted increase in MSNA (from 
44.1±2.4 to 50.1±6.4 bursts/100hb, p<0.05 vs baseline). The use of a different 
vasodilator (papaverine, 0.5 mg/Kg/h) exerted results superimposable to sodium 
nitroprusside. 
Conclusions: Endogenous endothelin-1 appears to have a sympatoexcitatory effect 
both in normotensive and hypertensive subjects through ETA receptors, contributing 
to the basal sympathetic vasomotor tone. Moreover essential hypertension shows an 
increased susceptibility to sympathoexcitatory effects of  endogenous ET-1.  
Key Words: hypertension • sympathetic nervous system • endothelin • 
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microneurography • BQ123 
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Introduction 
 
Essential hypertension is characterized by an increased sympathetic nervous system 
(SNS) activity, as clearly demonstrated by means of sensitive techniques, such as 
the norepinephrine spillover method[1] and the microneurographic quantification of 
nerve traffic[2]. SNS activation is already present in normotensive offspring of 
hypertensive patients[3], is peculiar of the essential hypertensive state[2], parallels 
the degree of blood pressure (BP) increase[2] and may exert deleterious metabolic 
and cardiovascular effects, accelerating the progression of the target organ damage 
associated with hypertension[4]. 
Endothelin-1 (ET-1) is a vasoconstrictor and mitogenic peptide produced by 
endothelial cells and its important role in regulation of vascular tone and structure is 
well established [5]. Essential hypertension is characterized by increased ET-1 
vasoconstrictor tone[6-7], which seems to be a consequence of reduced availability 
of nitric oxide (NO)[7]. ET-receptor antagonists, particularly those acting on ETA 
receptors, are a promising therapeutic option in patients with resistant[8] and 
renoparechimal[9] hypertension. The endothelin system role in cardiovascular 
homeostasis is not limited to its direct vascular effects, but involves also the neural 
regulation of vasomotor tone[10]. Experimental evidence suggests that ET-1 can 
stimulate central and peripheral SNS activity through ETA receptors[11-12]. While 
intracerebral administration of ET-1 can increase blood pressure and SNS activity 
mainly through ETA receptors in hypertensive as well in normotensive animals[11-12], 
the administration of an ETA receptor antagonist determines the opposite effect only 
in hypertensive animals, suggesting a specific sympathoexcitatory role for the 
endothelin system in this condition[11]. With regard to the peripheral autonomic 
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nervous system, ET-1 can act in carotid bodies and in cervical superior and nodose 
ganglia, influencing baroreflex and chemoreflex regulation; is released by post-
ganglionic sympathetic neurons, possibly modulating catecholamines release and 
vascular tone; and stimulates catecholamines release from adrenal glands[13]. 
Despite the growing body of evidence coming from experimental studies, few data 
are available about the systemic interaction between endogenous ET-1 and SNS in 
humans either in physiological or pathological conditions. Interestingly, local infusion 
of ET-1 is able to potentiate SNS-mediated vasoconstriction induced by deep 
breath[14]. Thus, we speculated that ET-1 could modulate sympathetic activity also 
in humans through ETA receptors, and that this interaction could be peculiar for the 
hypertensive status. For this purpose, we evaluated the effect of systemic ETA 
receptor blockade on SNS activity in healthy subjects and in patients with essential 
hypertension. 
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Methods 
 
Population 
 The present study included 15 essential hypertensive patients (HT), enrolled by the 
Hypertension outpatient Clinic of the University Hospital of Pisa, and 12 healthy 
subjects (NT), recruited among the hospital staff. 
The patients had never received any antihypertensive treatment and were 
characterized by mild essential hypertension (systolic BP between 140 and 159 
and/or diastolic BP between 90 and 99 mmHg on repeated clinic measurements), no 
history or physical or laboratory evidence of overt cardiovascular disease, target 
organ damage or major non cardiovascular diseases. Current cigarette smoking and 
daily assumption of three or more alcohol drinks were considered as exclusion 
criteria. Secondary hypertension was excluded by standard testing. The two groups 
were comparable for age, body mass index, glycemic and lipid profile and renal 
function (Table 1).  
The protocol of the study was approved by the local ethical committee and was in 
accordance with institutional guidelines. The patients gave their written informed 
consent to participate in the study after explanation of its nature and purpose.   
 
Measurements 
In each subject a detailed medical history and physical examination, BP (3 
measurements in the sitting position by means of the automatic device Omron 705IT) 
and heart rate, anthropometric parameters and routine blood sample assays  were 
measured before the inclusion in the study.  
During the experimental session, the following measurements were obtained:  
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1) beat-to-beat BP through a finger photoplethysmographic device (Finapres 2300, 
Ohmeda; Englewood, Colorado); 
2) beat-to beat heart rate, through a transthoracic ECG lead (Biotach, Gould 
Electronics; Valley View, Ohio);  
3) plasma norepinephrine (NE) and epinephrine (E), both assayed by high-pressure 
liquid chromatography[15], and ET-1, by enzyme immunoassay (Biomedica, Wien), 
on venous blood samples taken from an antecubital vein;  
4) multiunit recording of efferent postganglionic muscle sympathetic nerve activity 
(MSNA). Briefly, a tungsten microelectrode (diameter 200 μm), with a uninsulated 
1-5 μm diameter tip (Medical Instruments, University of Iowa; Iowa City) was 
transcutaneously inserted into the right or left peroneal nerve just posterior to the 
fibular head. A reference electrode was inserted subcutaneously 1-3 cm from the 
recording site. The signal was integrated with a 0.1 second – time constant, 
amplified with a gain of 50000-80000, band-pass filtered (700-2000 Hz) and 
acquired with a sampling rate of 1000 Hz through a digital acquisition system 
(ACQ-16, Gould Electronics; Valley View, Ohio). MSNA was identified according to 
the criteria outlined in previous studies[3, 16-17], and in detail: electrical stimulation 
(0.1 to 0.3 V, 0.1 ms, 1 Hz) through the electrode in the peroneal nerve elicited 
involuntary muscle contractions in the peroneal nerve but no paresthesia; tapping or 
stretching the innervated muscle region elicited afferent mechanoreceptor 
discharges, whereas stroking the skin did not; spontaneous pulse-sincronous 
bursts, that increase in frequency during voluntary apnoea but not after a loud 
noise, were displayed by the neurogram. The recording was considered acceptable 
if the signal-to-noise ratio exceeded the value of 3. The neurograms so obtained 
were recorded together with BP and heart rate by means of a dedicated computer 
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software (Ponemah, LDS; Valley View, Ohio). MSNA was quantified as bursts per 
minute (bursts/min) and bursts per 100 heart beats (bursts/100hb). MSNA 
recordings were analyzed by visual inspection by a single investigator, blinded 
about the protocol of the study and the infused drug. The coefficient of variation of 
MSNA at different time intervals in the same individual in our laboratory is 4.4%. 
During the recording, respiration rate was monitored through a strain-gauge 
pneumograph (Pneumotrace, Gould Electronics; Valley View, Ohio), positioned at 
the midchest level, in order to exclude from the data analysis any time interval in 
which respiratory rhythm alterations were present. 
 
Experimental protocol  
 
All experimental sessions were performed in the morning, and the subjects were 
asked to avoid smoking, caffeine- and alcohol-containing beverages, and eating for 
the 12 hours before the study. During the experimental session, the subjects were 
put in the supine position in a quiet and comfortable room and then fitted with an 
intravenous cannula, the microelectrodes for MSNA recording, and the other 
measuring devices. After a 30-minute interval, BP, heart rate, respiration rate, and 
MSNA were continuously monitored and recorded in baseline conditions and during 
infusion of a selective antagonist for ETA receptors, BQ-123 (Clinalfa, Bachem; Weil 
am Rhein, Germany), at the dose of 0.1 mg/Kg/h, and of a direct vasodilating agent, 
sodium nitroprusside (SNP; Malesci; Florence, Italy), at the dose of 0.4 µg/Kg/min. 
Each drug was infused for 20 minutes and was preceded by a 10-minute baseline 
acquisition. Because of the prolonged pharmacodynamic effect of  BQ123[18], it was 
not possible to randomize the two drug infusions in each experimental session. Thus 
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SNP, having a very short half-life, was always infused as the first drug, allowing a 30-
minute wash out period before the beginning of BQ123 infusion. In 4 NT and 6 HT, 
two experimental sessions were performed (separated by at least two weeks each 
other), administering in one session SNP and BQ123 and in the other session normal 
saline infusion (NaCl 0.9%), and the vasodilator drug papaverine (0.5 mg/kg/h i.v.). 
The order of the two sessions was randomized. The doses of SNP and papaverine 
were chosen according to preliminary studies in order to obtain the same BP 
reduction as BQ123 in the hypertensive population. Given the known smaller 
vasodilatory power of BQ123 in healthy subjects[9], 9 out of 12 NT underwent an 
adjunctive experimental session, administering BQ123 at the dose of 0.2 mg/kg/h.  
Blood samples for NE, E and ET-1 were collected at baseline and at the end of each 
drug infusion. 
 
Data Analysis 
Statistical analysis was performed by NCSS 2007 (Kaysville, Utah). Results are 
shown as mean ± standard deviation. Differences in baseline characteristics between 
groups were analyzed by unpaired t-test or χ2, as appropriate. BP, heart rate, and 
MSNA obtained in each subject were averaged for intervals of 10 minutes during the 
baseline period and of 5 minutes during drug infusion. Within each group, repeated 
measurements were analyzed by general linear model ANOVA, considering as 
factors time intervals and type of drug, and Fisher‘s LSD multiple comparison post-
hoc test. A p level less than 0.05 was used to define statistical significance. The 
sample size was calculated in order to reject the null hypothesis with a power of 0.8 
and a type I error probability of 0.05. The minimum number of patients required to 
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demonstrate a difference in MSNA of 6 bursts/100hb above baseline, with a standard 
deviation of 5 bursts/100hb, is 8 for each study group. 
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Results 
 
Baseline Values 
Table 1 shows the clinical characteristics of the study population. BP and MSNA 
values were, as expected, higher in HT as compared to NT. The other parameters 
were similar in the two groups.  
 
Hemodynamic parameters 
In HT, BP values were significantly reduced both by BQ123 (systolic BP from 
149.4±10.0 to 145.5±10.9 mmHg, p<0.01; diastolic BP from 91.1±7.5 to 87.8±7.6 
mmHg, p<0.05) and SNP (systolic BP from 150.9±11.7 to 146.1±13.0 mmHg, p<0.01; 
diastolic BP from 90.6±8.6 to 87.3±9.6 mmHg, p<0.05) to a similar extent (Figure 1a). 
On the contrary, in the control group SNP and BQ123 infusion exerted different 
results, since the former significantly reduced systolic (from 129.2±11.1 to 
125.5±11.8 mmHg; p<0.05) and diastolic BP (from 77.0±9.3 to 73.7±8.8 mmHg; 
p<0.05), whereas the latter did not modify BP values (systolic BP from 130.3±11.6 to 
129.2±12.6 mmHg, p=ns; diastolic BP from 76.9±9.8 to 76.6±9.7 mmHg, p=ns) 
(Figure 1b).  
In HT, heart rate was significantly increased both by BQ123 (from 69.8±10.8 to 
78.2±13.1 bpm, p<0.01) and SNP (from 71.1±8.8 to 80.0±12.4 bpm, p<0.01) (figure 
1e). In NT, heart rate was increased by SNP infusion (from 68.7±7.0 to 81.0±6.8 
bpm; p<0.001 vs baseline), to a greater extent as compared to HT (p<0.05 vs HT), 
despite a similar BP-lowering effect; BQ123 infusion caused a small but significant 
increase in heart rate (from 69.0±5.8 to 74.9±9.0 bpm, p<0.05) in absence of any BP 
change (figure 1f).  
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Hemodynamic responses to SNP and papaverine infusion were similar both within 
the hypertensive (systolic BP-3.2±1.9% vs -3.0±2.1%; diastolic BP -3.8±1.2% vs  
-3.2±2.1%; heart rate +11.3±5.5% vs +11.3±5.5%; p=ns for all) and the control group 
(systolic BP -3.1±2.4% vs -2.9±2.0%; diastolic BP -4.1±1.7% vs -4.6±1.8%; heart rate 
+18.3±6.3% vs +16.6±4.0%; p=ns for all). Placebo infusion did not exert any 
significant change in systolic BP (HT from 148.0±9.0 to 149.7±10.7 mmHg; NT 
126.4±12.7 to 126.0±10.3 mmHg; p=ns for all), diastolic BP (HT from 88.7±7.1 to 
87.0±8.9 mmHg; NT 78.0±10.4 to 77.0±10.4 mmHg; p=ns for all), or heart rate (HT 
from 69.4±8.2 to 70.6±9.4 bpm; NT 65.5±5.6 to 64.2±6.8 bpm; p=ns vs for all). 
 
Muscle sympathetic nerve activity 
In HT, even in presence of similar hemodynamic modifications, the effect of the two 
vasoactive drugs on MSNA was different. MSNA was significantly increased by SNP 
infusion (from 50.6±4.9 to 61.1±5.1 bursts/100hb, p<0.01). Of note, the increase in 
MSNA induced by BQ123 (from 52.0±4.9 to 56.8±5.5 bursts/100hb, p<0.05) was 
significantly lower (p<0.05) as compared to the one induced by SNP (Figure 2a).  
In NT, the effect of SNP infusion on MSNA (from 43.1±4.2 to 52.3±9.1 bursts/100hb, 
p <0.001) was similar to that observed in HT, while BQ123 infusion did not 
significantly modify MSNA (from 43.7±3.9 to 44.4±3.5 bursts/100hb, p=ns), as well as 
blood pressure (Figure 2b).  
SNP and papaverine infusion induced a similar MSNA increase within the 
hypertensive (+21.5±10.5% vs +23.7±9.0%; p=ns) and the control group 
(+22.4±13.4% vs +25.6±12.8%; p=ns). Finally, MSNA was not modified by placebo 
infusion either in HT (from 52.1±5.1 to 53.6±0.7 bursts/100hb, p=ns) or in NT (from 
44.9±2.7 to 46.4±5.0 bursts/100hb, p=ns).  
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Neurohumoral parameters 
At baseline, plasma concentrations of NE, E and ET-1 were similar in HT and in NT 
(Table 1). After infusion of BQ123 they were not significantly modified either in HT 
(NE 2.2±0.6 nmol/l, E 146±39 pmol/l, ET-1 1.9±0.3 fmol/l) or in NT (NE 1.9±0.8 
nmol/l, E 108±46 pmol/l, ET-1 1.6±0.6 fmol/l). Also infusion of SNP, placebo and 
papaverine did not modify plasma concentrations of the assayed parameters (data 
not shown). 
 
Responses to high dose BQ123 
In 9 NT the experimental session was repeated administering BQ123 at the dose of 
0.2 mg/kg/h, in order to obtain a significant BP-lowering effect. Higher doses of 
BQ123 effectively reduced BP (systolic BP from 130.1±7.1 to 124.6±6.7 mmHg, 
p<0.05; diastolic BP from 77.0±7.9 to 73.2±7.7 mmHg, p<0.05), as represented in 
figure 1b. BP decrease was comparable to that induced by SNP (p=ns), while the 
increase in heart rate (from 67.7±6.0 to 73.5±7.6 bpm, p<0.05), was still significantly 
smaller as compared to SNP (figure 1d). High-dose BQ123 also induced an increase 
in MSNA (from 44.1±2.4 to 50.1±6.4 bursts/100hb, p<0.05), which was blunted as 
compared with SNP (p<0.05, figure 2b). 
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Discussion 
 
The main finding of this study is that the reduction in BP induced by the acute 
intravenous administration of an ETA -antagonist produces a blunted increase in SNS 
activity in patients with essential hypertension and in healthy subjects. This finding 
suggests that endogenous ET-1, by the stimulation of ETA receptors, contributes to 
the basal sympathetic tone that controls vascular resistances in humans. Moreover in 
HT, as compared to NT, lower doses of BQ123 were sufficient to reveal the 
vasodilating and sympathoinhibitory effect of ETA blockade. Thus, our results confirm 
that endogenous ET-1 exerts a stronger vasoconstrictor effect in HT than in NT[7] 
and demonstrate for the first time that essential hypertension is characterized by a 
greater susceptibility to the sympathoexcitatory effect of endogenous ET-1. 
Because experimental studies pointed on the role of ETA receptors as the mediators 
of the effect of ET-1 on SNS[11-12], we decided to use a selective antagonist for this 
ET-receptor subtype. To distinguish a potential direct effect of BQ123 on sympathetic 
nerve activity from the aspecific, baroreflex-mediated, effect due to BP lowering per 
se, BQ123 was compared with SNP, a direct vasodilating drug. In patients with 
essential hypertension, both BQ123 and SNP induced a similar BP reduction, with a 
parallel increase in heart rate. Nevertheless, despite similar hemodynamic 
modifications, the increase in MSNA measured by microneurography was 
significantly smaller during BQ123 infusion than during SNP infusion. In other words, 
the expected baroreflex-mediated increase in MSNA, induced by any BP lowering 
drug, appeared to be blunted by a direct effect of the ETA blockade. Thus, ET-1 
seems to have a stimulating effect on sympathetic nerve activity through the 
activation of ETA receptor subtype.  
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When the same experimental protocol was applied to NT, SNP determined similar 
changes in BP and MSNA as compared to HT. In contrast, BP and MSNA were not 
modified by BQ123 administration. The absence of any hemodynamic effect in 
response to BQ123 infusion was expected according to the previous literature[9, 18-
19], indicating a less potent vasoconstrictor effect of endogenous ET-1 in NT than in 
patients with essential hypertension[6-7]. For that reason in NT we re-administered 
BQ123 at a higher dose, capable to induce the same BP reduction obtained in HT. In 
that conditions we observed a significant increase in MSNA, which however was 
blunted in comparison to that induced by SNP infusion. The results were further 
confirmed by the fact that another vasodilator, such as papaverine, exerted a similar 
BP and MSNA response as compared to SNP, thus highlighting the peculiarity of 
ETA-blockade effect and excluding a direct effect of exogenous NO released by SNP 
on sympathetic activity. 
Our results demonstrate that endogenous ET-1 contributes to the modulation of SNS 
activity both in physiological conditions and in essential hypertension. Furthermore, 
HT patients, which are characterized by an increased vasoconstriction to 
endogenous ET-1, as previously demonstrated by our group[7], present also a 
greater susceptibility to the sympatoexcitation due to endogenous ET-1. Taken 
together, these findings suggest that the increased biological activity of endogenous 
ET-1 of HT takes place in parallel in different systems, such as in the peripheral 
vasculature and in the SNS. Although the small entity of the BP reduction obtained 
with BQ123 infusion could suggest a limited relevance of the contribution of ET-1 in 
BP regulation, it is conceivable that the pressor effect of ETA antagonism might be 
buffered by baroreflex mechanisms in this population of relatively young subjects. 
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Experimental data support the hypothesis of a role of endogenous ET-1 in 
modulation of central sympathetic drive[11-12, 20-21], which is enhanced in some 
experimental models of hypertension[11, 22]. BQ123 is able to cross the blood-brain 
barrier, possibly through an active transport system[23], and thus to block ETA-
mediated effects of endogenous ET-1 in several sites within the central nervous 
system[13]. Moreover BQ123 could act on brain areas characterized by an 
incomplete blood-brain barrier, like area postrema[21], which could be a key site of 
action of ET-1 within central nervous system[24]. Another possible site of interaction 
could be at the level of sympathetic postganglionic neurons within the sympathetic 
ganglia[13].  
As expected, during SNP infusion the increase in heart rate was blunted in HT in 
comparison to NT, confirming the presence of a reduced heart rate-baroreflex gain, 
which is a well established feature of essential hypertension[2]. During administration 
of BQ123 in healthy subjects, an increase in heart rate was observed even in the 
absence of any BP modification, leading to different interpretations. Previous 
studies[9, 18] demonstrated that subpressor doses of BQ123 reduce systemic 
vascular resistances, possibly via activation of cardiopulmonary reflexes. Another 
hypothesis is a direct chronotropic effect, recently highlighted in healthy conscious 
rats after the administration of the non selective ETA-ETB receptor antagonist 
bosentan[25].  
Interestingly, using higher doses of BQ123 in order to induce a significant 
hemodynamic effect, BP reduction was accompanied by a blunted heart rate 
response as compared to SNP. Pedersen and colleagues found a superimposable 
heart rate increase as compared to our results, but they attributed it only to the reflex 
response to vasodilation, because they did not compare BQ123 effect with another 
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vasodilator[19]. Our results are in agreement with experimental observations in which 
ET-1 increased heart rate-baroreflex gain [26-27], while bosentan administration 
caused opposite effects [25]. These data suggest a specific physiological role for ETA 
receptors in regulation of heart rate, which is not evident in essential hypertension 
and needs to be further investigated. 
 
Plasma NE concentrations were not significantly modified during the infusion of 
BQ123 in HT as well as in NT. However this result is not necessarily in contradiction 
with MSNA results, because plasma NE can be considered only a very rough index 
of the spillover of the neurotransmitter from vascular sympathetic terminations[28]. 
Moreover the endothelin system modulates NE release at presynaptic sympathetic 
nerve endings, but also from the adrenal glands[13], further limiting the use of 
plasma NE for the estimation of sympathetic activity in the present study. 
Plasma ET-1 concentrations, according to literature, were similar in HT and NT[29] 
and they were not modified by BQ123[18]. This observation could be explained by 
the fact that plasma levels of the peptide does not reflect its biological activity, since 
ET-1 is released mainly abluminally and removed by plasma mainly by binding with 
ETB receptors[5].  
Among the limitations of the study, it has to be taken into account the short-lasting 
monitoring of the hemodynamic parameters and of MSNA. The study was designed 
according to previous studies[18], showing that the time interval is sufficient to obtain 
detectable hemodynamic changes. However, since this is the first study exploring 
sympathetic nerve activity during ETA inhibition, we cannot exclude further MSNA 
variations in the following period. Our findings are also limited by the absence of any 
measurement of central venous pressure, a key determinant of sympathetic activity. 
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While it is well established that the SNP-induced sympathoexcitation is determined 
both by BP and central venous pressure reduction, little information is available about 
the effects of ETA blockade. Dorsal hand venoconstriction to ET-1 is greater in HT 
than in NT[14]. Thus, it is conceivable that ET-1-inhibition should result in a greater 
increase in venous capacitance and reduction in central venous pressure in HT than 
in NT, in parallel to what happens in the arterial district. On the other hand, since 
sympathetically mediated venoconstriction is potentiated by ET-1 in HT in 
comparison to NT[14], we can speculate that ET-antagonism could blunt sympathetic 
responses to central venous pressure changes. Thus, the ET/SNS interaction in the 
venous district could contribute to the blunted MSNA response to BQ123 in HT in the 
present study.  
 
Perspectives 
Our results demonstrate that endogenous ET-1 has a sympatoexcitatory effect both 
in physiological conditions and in essential hypertension, possibly contributing to the 
basal sympathetic outflow regulating vasomotor tone. Furthermore, essential 
hypertension appears to be characterized by an increased susceptibility to the 
sympathoexcitatory effect of endogenous ET-1. Thus, the discovery of an enhanced 
biological activity of ET-1 on autonomic cardiovascular regulation, beyond the known 
effects on vascular tone, further reinforces the fundamental role of the endothelin 
system in the pathophysiology of essential hypertension and of the related organ 
damage. Thus, treatment options aimed at contrasting the endothelin system could 
favourably influence adrenergic overactivity characterizing essential hypertension.  
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Figures legend 
Figure 1: The figure shows the behavior of systolic blood pressure (figure 1a and 1 b) 
and heart rate (figure 1c and 1d) during the experimental sessions in hypertensive 
patients, on the left, and in normotensive subjects, on the right. Empty circles 
represent data during SNP infusion, black circles during BQ123 infusion at 0.1 
mg/kg/h and grey circles during BQ123 infusion at 0.2 mg/kg/h. Data are shown as 
mean±SEM. BP: blood pressure; * p<0.05 vs baseline; † p<0.05 vs SNP. 
 
Figure 2: The figure shows the behavior of muscle sympathetic nerve activity during 
the experimental sessions in hypertensive patients (2a), and in normotensive 
subjects (2b). Empty circles represent data during SNP infusion, black circles during 
BQ123 infusion at 0.1 mg/kg/h and grey circles during BQ123 infusion at 0.2 
mg/kg/h. Data are shown as mean±SEM.  
MSNA: muscle sympathetic nerve activity; b/100hb bursts: per 100 heart beats; * 
p<0.05 vs baseline; † p<0.05 vs SNP.  
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Table 1. Clinical characteristics of the Study Population 
 Hypertensive 
Patients 
(n=15) 
Normotensive 
Subjects 
(n=12) 
 
Age (years) 
 
45.8±6.8 
 
43.5±5.6 
Gender (M/F) 11/4 9/3 
Systolic BP (mmHg) 150.9±11.7* 130.1±7.1 
Diastolic BP (mmHg) 90.6±8.6* 82.0±7.9 
Heart rate (bpm) 71.1±8.8 68.7±7.0 
MSNA (bursts/min) 34.1±8.9* 29.4±2.4 
MSNA (bursts/100hb) 50.6±9.9* 43.1±4.2 
BMI (Kg/m2) 23.8±4.1 22.2±3.5 
Total Cholesterol (mmol/l) 5.1±0.9 5.0±0.6 
HDL-cholesterol  (mmol/l) 1.2±0.4 1.3±0.5 
LDL-cholesterol (mmol/l) 3.0±0.6 2.8±0.7 
Blood glucose (mmol/l) 5.2±0.2 4.9±0.4 
Plasma creatinine (µmol/l) 80.0±13.1 78.3±9.1 
NE (nmol/l) 1.9±0.6 1.6±0.8 
E (pmol/l) 147±27 121±42 
ET-1 (fmol/l) 1.7±0.5 1.7±0.8 
 
M: male; F: female; BP: blood pressure; MSNA: muscle sympathetic nervous activity; BMI: 
body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NE: 
norepinephrine; E: epinephrine; ET-1: endothelin-1; *: p<0.05 vs normotensive subjects. 
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